Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based studyKuniko Sunami, Takashi Kohno, Momoko Nagai et al.|Cancer Science|2019Cited by 375
First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid TumorsToshio Shimizu, Noboru Yamamoto, Yutaka Fujiwara et al.|Clinical Cancer Research|2021Cited by 97
Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I studyShunji Takahashi, Noboru Yamamoto, Yutaka Fujiwara et al.|Cancer Science|2021Cited by 72
Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumorsYonina R. Murciano‐Goroff, Joshua K. Sabari, Rebecca S. Heist et al.|Cancer Research|2023Cited by 37
High-Throughput Functional Evaluation of <i>MAP2K1</i> Variants in CancerSho Mizuno, Shinji Kohsaka, Masachika Ikegami et al.|Molecular Cancer Therapeutics|2022Cited by 32